AU2016322506B2 - Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof - Google Patents

Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof Download PDF

Info

Publication number
AU2016322506B2
AU2016322506B2 AU2016322506A AU2016322506A AU2016322506B2 AU 2016322506 B2 AU2016322506 B2 AU 2016322506B2 AU 2016322506 A AU2016322506 A AU 2016322506A AU 2016322506 A AU2016322506 A AU 2016322506A AU 2016322506 B2 AU2016322506 B2 AU 2016322506B2
Authority
AU
Australia
Prior art keywords
ccl22
seq
cells
peptide
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016322506A
Other languages
English (en)
Other versions
AU2016322506A9 (en
AU2016322506A1 (en
Inventor
Mads Hald Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of AU2016322506A1 publication Critical patent/AU2016322506A1/en
Publication of AU2016322506A9 publication Critical patent/AU2016322506A9/en
Assigned to IO BIOTECH APS reassignment IO BIOTECH APS Request for Assignment Assignors: HERLEV HOSPITAL
Application granted granted Critical
Publication of AU2016322506B2 publication Critical patent/AU2016322506B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2016322506A 2015-09-16 2016-09-16 Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof Active AU2016322506B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570591 2015-09-16
DKPA201570591 2015-09-16
PCT/DK2016/050301 WO2017045691A1 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Publications (3)

Publication Number Publication Date
AU2016322506A1 AU2016322506A1 (en) 2018-04-12
AU2016322506A9 AU2016322506A9 (en) 2018-12-06
AU2016322506B2 true AU2016322506B2 (en) 2023-02-09

Family

ID=57123753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016322506A Active AU2016322506B2 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof

Country Status (8)

Country Link
US (3) US11298413B2 (enExample)
EP (1) EP3349785A1 (enExample)
JP (1) JP6924747B2 (enExample)
CN (2) CN108472345B (enExample)
AU (1) AU2016322506B2 (enExample)
HK (1) HK1257448A1 (enExample)
IL (1) IL257940B (enExample)
WO (1) WO2017045691A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccines that include the CC motif. Chemokine 22 or fragments thereof
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
WO2022022756A1 (es) * 2020-07-30 2022-02-03 Centro De Inmunologia Molecular Uso de agentes depletantes del factor de crecimiento epidérmico en el tratamiento de la enfermedad pulmonar obstructiva crónica
WO2024168311A2 (en) * 2023-02-09 2024-08-15 The Brigham And Women’S Hospital, Inc. Autonomous gene circuits for therapy release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
AU708743B2 (en) 1995-06-07 1999-08-12 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US8563476B2 (en) * 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
EP2628749A3 (en) * 2006-06-20 2013-12-04 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compostions and methods of use
DK2280721T3 (da) 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
WO2011006029A1 (en) * 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
ES2918580T3 (es) 2011-10-17 2022-07-19 Io Biotech Aps Inmunoterapia basada en PD-L1
WO2013103658A1 (en) 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US20150359869A1 (en) 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition
HK1212448A1 (en) * 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
EP3461491B1 (en) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
US10130454B2 (en) 2014-08-01 2018-11-20 Iowa State University Research Foundation, Inc. Vaccine delivery devices
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccines that include the CC motif. Chemokine 22 or fragments thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUO J ET AL: "MACROPHAGE-DERIVED CHEMOKINE GENE TRANSFER RESULTS IN TUMOR REGRESSION IN MURINE LUNG CARCINOMA MODEL THROUGH EFFICIENT INDUCTION OF ANTITUMOR IMMUNITY", GENE THERAPY, vol. 9, no. 12, 1 June 2002 (2002-06-01), pages 793 - 803 *

Also Published As

Publication number Publication date
US11298413B2 (en) 2022-04-12
US20220280624A1 (en) 2022-09-08
EP3349785A1 (en) 2018-07-25
HK1257448A1 (zh) 2019-10-18
JP6924747B2 (ja) 2021-08-25
WO2017045691A1 (en) 2017-03-23
CA2998789A1 (en) 2017-03-23
NZ740930A (en) 2024-09-27
US12551543B2 (en) 2026-02-17
US20230241191A9 (en) 2023-08-03
JP2018528960A (ja) 2018-10-04
WO2017045691A9 (en) 2018-06-28
US20190008939A1 (en) 2019-01-10
US20220339273A1 (en) 2022-10-27
AU2016322506A9 (en) 2018-12-06
IL257940B (en) 2022-08-01
IL257940A (en) 2018-05-31
CN116333088A (zh) 2023-06-27
US12496333B2 (en) 2025-12-16
AU2016322506A1 (en) 2018-04-12
CN108472345B (zh) 2023-05-23
CN108472345A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
US12233103B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
US12551543B2 (en) Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
BR112014009526B1 (pt) Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
CA2998789C (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: IO BIOTECH APS

Free format text: FORMER APPLICANT(S): HERLEV HOSPITAL

FGA Letters patent sealed or granted (standard patent)